ESMO 2025
October 17, 2025 - October 21, 2025
Berlin, Germany
As the fall conference season ramps up, Nordic Bioscience’s oncology team is pleased to be attending the ESMO Congress 2025, held October 17–21 in Berlin, Germany.
ESMO continues to be a cornerstone for oncology innovation, bringing together researchers and clinicians to shape the future of cancer care. Nordic Bioscience will take part in this year’s program with a focus on biomarker-driven strategies in oncology—particularly the role of tumor fibrosis in shaping treatment response.
A highlight of our contribution is the ongoing development and regulatory support for nordicPRO-C3™, a novel blood-based biomarker targeting collagen remodeling in the tumor microenvironment. Backed by a Letter of Support from the FDA, nordicPRO-C3™ enables non-invasive monitoring of cancer-associated fibroblast (CAF) activity, which plays a central role in tumor progression, drug resistance, and immunotherapy response.
We look forward to exchanging ideas and building new collaborations during this key event in the oncology calendar.
